Effect of Proton Pump Inhibitors on Palpitations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Palpitation is a common complaint. Patients frequently feel this symptom despite having normal rhythm during symptoms. I have seen many patients who improve significantly on treatment with proton pump inhibitors (PPI). It may be that gastritis provokes a feeling of discomfort that subsequently starts the feeling of palpitation. On searching literature I found no study that investigated the effect of PPI's on palpitations. Therefore I propose a study where the investigators randomize people with palpitations with normal heart rate (no arrhythmia) and no apparent cause such as anxiety or clear illness to receive either PPI or placebo. The result will help to investigate if the improvement is true and if the results are positive this can provide a simple treatment for a common problem.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

NCT00378287

GERD

COMPLETED PHASE1

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

NCT02097329

Healthy

COMPLETED PHASE1

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

NCT03220191

Healthy Volunteer

COMPLETED PHASE1

PPI's and SSRI's Therapy for the Management of NCCP

NCT02825342

Chest Pain Rule Out Myocardial Infarction

TERMINATED PHASE4

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00037570

Peptic Ulcer Hemorrhage

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods Two hundred patients with palpitations and no clear cause for their symptoms will be randomized to receive either PPI or placebo for one month. At base line they will be investigated to rule out arrhythmia by documenting normal heart rate (less than 110 beat per minute) or ECG showing normal sinus rhythm or mild sinus tachycardia (Less than 110 per minute) during symptoms. Obvious causes such as anxiety due to a stressful event or organic causes such anemia or thyroid disorders should be also ruled out.

Patient who agree to participate in the study will be asked to sign an informed consent. A baseline questionnaire with symptoms will be filled. They will then be randomized for treatment with either PPI or placebo once at night time. After 10 days of treatment they will be contacted and questioned regarding their symptoms. The two groups will be compared to see if there is any improvement of symptoms with treatment.

Studying group The study will be under the umbrella of the JCC group. Primary investigators are Dr Munir Zaqqa and Dr Ismail Hamam

Support required Pharmaceutical company will be contacted to provide 120 packets with 30 tabs of PPI and if possible packets with similar matching placebo to support the study

Study criteria inclusion

1. Persons with palpitations and no clear cause who are above the age of 16 years and who consent to the study will be included
2. Clear causes that should be excluded are true arrhythmia such SVT or VT or frequent premature atrial or ventricular contractions or any organic cause such as thyroid disorder, anemia (hg less than 11 g/dl) and obvious anxiety disorder
3. Arrhythmia can be excluded by an ECG showing sinus rhythm or sinus tachycardia during episodes or measurement of heart rate by a reliable method during symptoms showing regular heart rate less than 120 beats per minute.
4. Patient will be randomized to either PPI or placebo to be taken one table at night time
5. Patients will be provided with 2 weeks supply but will be evaluated at 10 days to see if symptoms improved
6. The two groups will be compared using statistical methods to see if there is difference in improvement.

Expected harm:

PPI's are generally safe medications. Side effects are rare and generally mild. They include nausea, stomach pain, diarrhea, constipation or headache.

Very rarely allergic reaction can occur with hives, difficulty in breathing and swelling of the face and lips.

Benefit to the patient:

Patients randomized to either group may experience benefit due to the medication or even placebo use. There is no financial benefit of participating in the study. The result of the study will be used to help patient in the future with similar symptoms

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Signs and Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active group

Will receive Rabeprazole sodium (Proton pump inhibitor 20 mg once daily)

Group Type ACTIVE_COMPARATOR

Rabeprazole sodium

Intervention Type DRUG

WIll study effect of the medication on palpittions

Placebo group

Will receive Folic acid 5 mg once daily

Group Type PLACEBO_COMPARATOR

Pacebo

Intervention Type DRUG

Placebo comparison to active treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rabeprazole sodium

WIll study effect of the medication on palpittions

Intervention Type DRUG

Pacebo

Placebo comparison to active treatment

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Active treatment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Persons with palpitations and no clear cause who are above the age of 16 years and who consent to the study will be included
2. Clear causes that should be excluded are true arrhythmia such SVT or VT or frequent premature atrial or ventricular contractions or any organic cause such as thyroid disorder, anemia (hg less than 11 g/dl) and obvious anxiety disorder
3. Arrhythmia can be excluded by an ECG showing sinus rhythm or sinus tachycardia during episodes or measurement of heart rate by a reliable method during symptoms showing regular heart rate less than 120 beats per minute.
4. Patient will be randomized to either PPI or placebo to be taken one table at night time
5. Patients will be provided with 2 weeks supply but will be evaluated at 10 days to see if symptoms improved
6. The two groups will be compared using statistical methods to see if there is difference in improvement.